The principles of engineering immune cells to treat cancer

• Carl June ; Wendell A. Lim ^[1]
  1. [1] University of California
• Localización: Cell, ISSN 0092-8674, Vol. 168, Nº. 4, 2017 (Ejemplar dedicado a: Cancer, the road ahead), págs. 724-740
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Chimeric antigen receptor (CAR) T cells have proven that engineered immune cells can serve as a powerful new class of cancer therapeutics. Clinical experience has helped to define the major challenges that must be met to make engineered T cells a reliable, safe, and effective platform that can be deployed against a broad range of tumors. The emergence of synthetic biology approaches for cellular engineering is providing us with a broadly expanded set of tools for programming immune cells. We discuss how these tools could be used to design the next generation of smart T cell precision therapeutics.